E-ISSN 2651-3455 (Online) | ISSN 2630-5593 (Print)
Volume : Issue : Year : 2020

Quick Search




The Anatolian Journal of Family Medicine Effects of Pancreatin therapy on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus [anatol j fm]
anatol j fm. 2020; 3(3): 229-233 | DOI: 10.5505/anatoljfm.2020.25349

Effects of Pancreatin therapy on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus

Reşat Dabak1, Engin Ersin Şimşek2, Sabah Tüzün2, Can Öner2, Ismet Tamer3, Ekrem Orbay2, Oya Bayramiçli4
1Department of Family Medicine, Istanbul Haseki Training and Research Hospital, Istanbul, Turkey
2Department of Family Medicine, Kartal Dr. Lutfi Kırdar City Hospital, Istanbul, Turkey
3Department of Family Medicine, Istinye University Faculty of Medicine, Istanbul, Turkey
4Private Office, Istanbul, Turkey

INTRODUCTION: Gastrointestinal symptoms (GIS) are more common in individuals with type 2 diabetes mellitus (DM) in comparison to normal population. This study aimed to evaluate the effects of the pancreatin therapy on the GIS in patients with type 2 DM.
METHODS: This study included patients with type 2 DM admitted to the Gastroenterology Department between February to July 2017. Age, HbA1c, level of C-peptide, triglyceride, antidiabetic treatments, fecal elastase levels were evaluated in the files of all patients. The GIS of the patients, who were considered to suffer from the exocrine pancreatic insufficiency, including abdominal pain, bloating, constipation and diarrhea were evaluated before and after the 25000 IU pancreatin therapy.
RESULTS: The study included 35 patients with type 2 DM, the mean age was 59.1±7.6 years, and 24 (68.6%) of the patients were female. The exocrine pancreatic insufficiency was detected in 1 (2.9%) of the patients. Prior to the pancreatin therapy, 33 (94.3%) of the patients were determined to have abdominal pain, 34 (97.1%) had bloating, 33 (94.3%) had constipation and 32 (91.4%) had diarrhea. After the therapy, 29 (82.9%) of the patients were found to have abdominal pain, 31 (88.6%) had bloating, 31 (88.6%) had constipation and 29 (82.9%) had diarrhea. GIS including abdominal pain, bloating, constipation and diarrhea were decreased after pancreatin treatment (p=0.015, p<0.001, p=0.001 and p=0.024, respectively).
DISCUSSION AND CONCLUSION: GIS in patients with type 2 DM can be treated with pancreatic enzyme replacement therapy.

Keywords: Abdominal pain, constipation, diarrhea, exocrine pancreatic insufficiency

Reşat Dabak, Engin Ersin Şimşek, Sabah Tüzün, Can Öner, Ismet Tamer, Ekrem Orbay, Oya Bayramiçli. Effects of Pancreatin therapy on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus. anatol j fm. 2020; 3(3): 229-233

Corresponding Author: Reşat Dabak, Türkiye
LookUs & Online Makale